CSL Behring Gets Indication For Acquired Factor XIII Deficiency For Fibrogammin P In Japan
This article was originally published in PharmAsia News
Executive Summary
CSL Behring on Sept. 13 obtained approval in Japan for the use of plasma derivative Fibrogammin P, the purified concentrate of blood coagulation factor XIII, for the treatment of bleeding caused by acquired factor XIII deficiency.
You may also be interested in...
PhRMA Sues To Block HHS Drug Importation Rule Citing Security, Safety, First Amendment Concerns
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.
Ulta CEO On Target Corp Partnership: ‘Now Is The Time For Innovation In Retail”
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Need a specific report? 1000+ reports available
Buy Reports